Duke Cancer Institute

Research Programs

Quick Links

Breadcrumbs Navigation

Home > Clinical Trials > Pediatric Clinical Trials - Pediatric Phase I/II (new anti-cancer drugs)

Jumbo Large Regular Text:

Clinical Trials

Pediatric Clinical Trials - Pediatric Phase I/II (new anti-cancer drugs)

If you would like to inquire about all open trials, please contact 919-684-3401.

Items 1 - 7 of 7

AAML08B1 Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
Principal Investigator: Susan Kreissman
Phase: N/A
Phone: 919-684-3401

AREN0321 Treatment of High Risk Renal Tumors
Principal Investigator: Susan Kreissman
Phase: N/A
Phone: 919-684-3401

NANT2007-02 A Phase I Study of Bevacizumab with Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children with Recurrent or Refractory Neuroblastoma
Principal Investigator: Susan Kreissman
Phase: Phase I
Phone: 919-684-3401

NANT2008-02 A Phase 1 Study of Vorinostat in Combination with 13-cis-retinoic acid in Patients with Refractory/Recurrent Neuroblastoma (IND#79176)
Principal Investigator: Susan Kreissman
Phase: Phase I
Phone: 919-684-3401

AALL07P1 A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Principal Investigator: Susan Kreissman
Phase: Phase II
Phone: 919-684-3401

ACNS1123 Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Principal Investigator: Susan Kreissman
Phase: Phase II
Phone: 919-684-3401

ARST0921 A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma
Principal Investigator: Susan Kreissman
Phase: Phase II
Phone: 919-684-3401